158 trials (keyword fallback)
Congenital Nasolacrimal Duct Obstruction
Primary: Change in Physician-rated Scale of NLDO From Baseline to Follow-Up Visit at Week 8 or From Baseline to Time of Treatment Failure, if Earlier. — 7; 10; 1; 1 participants
Cholecystitis · Cholelithiasis
Primary: Detection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red Light — 64; 157; 159; 243 Participants
Inoperable Tumors of the Bile Duct
Primary: Time to Recurrent Biliary Obstruction — 711; 357 days — p=0.530
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Progression-Free Survival — 51 percentage of participants
Nasolacrimal Duct Obstruction
Primary: Proportion of Participants With Treatment Success — 0.92; 0.82 proportion of participants — p=0.09
Cholestasis, Extrahepatic
Primary: Adequate Clinical Palliation of the Biliary Obstruction — 54 participants
Biliary Strictures Caused by Malignant Neoplasms
Primary: Number of Participants With Absence of Recurrent Biliary Obstruction — 62 Participants
Distal Bile Duct Obstruction
Primary: Rate of Long-term Stent Failure — 0; 2 Participants
Common Bile Duct Stricture
Primary: Early Clinical Success — 50; 41 Participants
Advanced Biliary Tract Carcinoma
Primary: MTD of MEK162 - Phase I — 45 mg
Patent Ductus Arteriosus (PDA)
Primary: Reporting of Late Adverse Events Relating to the Device. — 9 participant
Intrahepatic Cholangiocarcinoma
Primary: Number of Participants With Tumor Complete Response (CR) — 7 Participants
Gallbladder Carcinoma · Metastatic Cholangiocarcinoma · Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Progression Free Survival (PFS) — 0; 3; 39; 35 Participants — p=0.027
Bile Duct Cancer · Intrahepatic Cholangiocarcinoma · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Median Progression Free Survival (PFS) — 1.8 months
Constipation, Impaction, and Bowel Obstruction · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Number of Days Alive and Outside of the Hospital — 42.6; 43.9; 54.8; 52.7 days — p=0.50